File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Long-term prospective randomised study of hepatitis B vaccines without booster dose in children

TitleLong-term prospective randomised study of hepatitis B vaccines without booster dose in children
Authors
Issue Date2009
PublisherHong Kong Academy of Medicine
Citation
14th Medical Research Conference, Hong Kong, 10 January 2009. In Hong Kong Medical Journal, 2009, v. 15 n. S1, p. 7 How to Cite?
AbstractIntroduction: Protective antibodies persisted up to 10 to 15 years after primary hepatitis B virus (HBV) vaccination. Titres of antibody against HBV surface antigen (anti-HBs) decrease with time. Necessity for routine booster dose remains controversial. Immunogenicity and efficacy of HBV vaccination without booster dose was examined in the present study. Methods: From 1984 to 1986, 318 Chinese children from HBV families aged 3 months to 11 years old were randomised into one of the three HBV vaccine regimens without booster doses—group A: 2-dose recombinant; group B: 3-dose recombinant; group C: 3-dose plasma-derived vaccines. HBV surface antigen (HBsAg) titres, anti-HBs, and antibody against HBV core antigen (anti-HBc), were measured yearly. Results: After 22 years, no subject was found to be HBsAg positive. Geometric mean titre (GMT) of antiHBs of group A subjects was significantly lower than that of group B and C subjects at year 1, 5, 10, and 15. No difference was observed in the GMTs between group B and C throughout the 22 years. At year 22, the proportion of subjects with anti-HBs ≥10 mIU/mL (the protective level) for groups A, B and C were 35.3%, 76.5%, and 52.4% respectively. The difference was statistically significant between groups A and B. A total of 72 subjects had ≥1 episodes of anamnestic response with rises in anti-HBs titres after the primary vaccination during the 22 years study period. Of these, eight anamnestic responses were mounted from subjects with the preceding antiHBs titre <10 mIU/mL. Three subjects became positive for anti-HBc. Conclusion: Protective anti-HBs persisted up to 22 years after HBV vaccination without the use of booster dose. The 3-dose regimens have a better long-term immunogenicity. However, the 2-dose recombinant HBV vaccine was not inferior to 3-dose vaccines in terms of protection against chronic HBV infection. Booster doses were not necessary, due to long-term immune memory.
Persistent Identifierhttp://hdl.handle.net/10722/62318
ISSN
2015 Impact Factor: 0.887
2015 SCImago Journal Rankings: 0.279

 

DC FieldValueLanguage
dc.contributor.authorBut, Den_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorLim, WLen_HK
dc.contributor.authorFung, JYYen_HK
dc.contributor.authorWong, DKHen_HK
dc.contributor.authorYuen, RMFen_HK
dc.date.accessioned2010-07-13T03:58:42Z-
dc.date.available2010-07-13T03:58:42Z-
dc.date.issued2009en_HK
dc.identifier.citation14th Medical Research Conference, Hong Kong, 10 January 2009. In Hong Kong Medical Journal, 2009, v. 15 n. S1, p. 7-
dc.identifier.issn1024-2708-
dc.identifier.urihttp://hdl.handle.net/10722/62318-
dc.description.abstractIntroduction: Protective antibodies persisted up to 10 to 15 years after primary hepatitis B virus (HBV) vaccination. Titres of antibody against HBV surface antigen (anti-HBs) decrease with time. Necessity for routine booster dose remains controversial. Immunogenicity and efficacy of HBV vaccination without booster dose was examined in the present study. Methods: From 1984 to 1986, 318 Chinese children from HBV families aged 3 months to 11 years old were randomised into one of the three HBV vaccine regimens without booster doses—group A: 2-dose recombinant; group B: 3-dose recombinant; group C: 3-dose plasma-derived vaccines. HBV surface antigen (HBsAg) titres, anti-HBs, and antibody against HBV core antigen (anti-HBc), were measured yearly. Results: After 22 years, no subject was found to be HBsAg positive. Geometric mean titre (GMT) of antiHBs of group A subjects was significantly lower than that of group B and C subjects at year 1, 5, 10, and 15. No difference was observed in the GMTs between group B and C throughout the 22 years. At year 22, the proportion of subjects with anti-HBs ≥10 mIU/mL (the protective level) for groups A, B and C were 35.3%, 76.5%, and 52.4% respectively. The difference was statistically significant between groups A and B. A total of 72 subjects had ≥1 episodes of anamnestic response with rises in anti-HBs titres after the primary vaccination during the 22 years study period. Of these, eight anamnestic responses were mounted from subjects with the preceding antiHBs titre <10 mIU/mL. Three subjects became positive for anti-HBc. Conclusion: Protective anti-HBs persisted up to 22 years after HBV vaccination without the use of booster dose. The 3-dose regimens have a better long-term immunogenicity. However, the 2-dose recombinant HBV vaccine was not inferior to 3-dose vaccines in terms of protection against chronic HBV infection. Booster doses were not necessary, due to long-term immune memory.-
dc.languageengen_HK
dc.publisherHong Kong Academy of Medicine-
dc.relation.ispartofHong Kong Medical Journal-
dc.titleLong-term prospective randomised study of hepatitis B vaccines without booster dose in childrenen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.emailFung, JYY: jfung@sicklehut.comen_HK
dc.identifier.emailWong, DKH: danywong@hku.hken_HK
dc.identifier.emailYuen, RMF: mfyuen@hkucc.hku.hken_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.identifier.authorityFung, JYY=rp00518en_HK
dc.identifier.authorityWong, DKH=rp00492en_HK
dc.identifier.authorityYuen, RMF=rp00479en_HK
dc.identifier.hkuros158490en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats